We have identified and characterized potent and specific inhibitors of gera
nylgeranyl-protein transferase type I (GGPTase I), as well as dual inhibito
rs of GGPTase I and farnesyl-protein transferase. Many of these inhibitors
require the presence of phosphate anions for maximum activity against GGPTa
se I in vitro, Inhibitors with a strong anion dependence were competitive w
ith geranylgeranyl pyrophosphate (GGPP), rather than with the peptide subst
rate, which had served as the original template for inhibitor design. One o
f the most effective anions was ATP, which at low millimolar concentrations
increased the potency of GGPTase I inhibitors up to several hundred-fold.
In the case of clinical candidate L-778,123, this increase in potency was s
hown to result from two major interactions: competitive binding of inhibito
r and GGPP, and competitive binding of ATP and GGPP, At 5 mM, ATP caused an
increase in the apparent K-d for the GGPP-GGPTase I interaction from 20 pM
to 4 nM, resulting in correspondingly tighter inhibitor binding. A subset
of very potent GGPP-competitive inhibitors displayed slow tight binding to
GGPTase I with apparent on and off rates on the order of 10(6) M-1 s(-1) an
d 10(-3) s(-1) respectively, Slow binding and the anion requirement suggest
that these inhibitors may act as transition state analogs. After accountin
g for anion requirement, slow binding, and mechanism of competition, the st
ructure-activity relationship determined in vitro correlated well with the
inhibition of processing of GGPTase I substrate Rap1a in vivo.